

**Supplementary Table 1: Baseline Characteristics of Study Participants with HIV-Associated NAFLD**

	<b>Overall Sample</b> (n = 58)	<b>Placebo Group Only</b> (n = 24)
<b>Demographics</b>		
Age (years)	53 ± 7	53 ± 7
% Male	81	83
Race		
% Black	29	33
% White	66	63
% Hispanic	16	8
% Current smoker	17	29
% Ever smoker	59	63
<b>HIV-related indices</b>		
Duration of HIV (years)	16 ± 9	18 ± 9
CD4 count (cells/mm <sup>3</sup> )	763 ± 279	774 ± 277
log HIV viral load	0.39 ± 0.66	0.49 ± 0.74
% NRTI use	93	100
% NNRTI use	40	38
% PI use	24	21
% Integrase inhibitor use	62	58
<b>Immunologic indices</b>		
CRP (mg/L)	6.2 ± 7.8	4.2 ± 3.5
IL-6 (pg/mL)	1.5 ± 1.6	1.9 ± 2.2
<b>Hepatic indices</b>		
Liver fat (%)	13.8 ± 8.6	14.5 ± 9.7
% NASH	33	33
NAS score	2.7 ± 1.6	2.8 ± 1.7
Lobular inflammation	1.2 ± 0.6	1.2 ± 0.4
Hepatocellular ballooning	0.3 ± 0.7	0.4 ± 0.7
Liver biopsy length (mm)	13 ± 3	13 ± 3
ALT (U/L)	30 ± 22	26 ± 19
AST (U/L)	32 ± 22	36 ± 29
FIB-4	1.45 ± 0.81	1.55 ± 0.74
<b>Metabolic indices</b>		
BMI (kg/m <sup>2</sup> )	31 ± 6	32 ± 6
Waist circumference (cm)	110 ± 13	113 ± 12
Visceral fat (cm <sup>2</sup> )	243 ± 99	247 ± 109
Subcutaneous fat (cm <sup>2</sup> )	300 ± 146	324 ± 136
Fasting glucose (mg/dL)	96 ± 17	93 ± 12
HbA1c (%)	5.7 ± 0.5	5.7 ± 0.6
Triglycerides (mg/dL)	142 ± 69	130 ± 49

Variables are expressed as mean ± SD.

*Abbreviations:* ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; HbA1c, hemoglobin A1c; IL-6, interleukin-6; NAS score, NAFLD Activity Score; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.